HiweMed Completes Tens of Millions RMB Series A Financing to Advance Innovative Microsphere-Based Therapeutics

Recently, Suzhou Haowei Microbial Medical Technology Co., Ltd. (hereinafter referred to as “Haowei Microbial” or the “Company”) announced the completion of its Series A financing round, raising tens of millions of yuan.This round of financing was led by Jinyu Maowu Investment Management, with follow-on investments from Nanjing Venture Capital and Wuxi Capital Group. BITOLA CAPITAL served as the exclusive financial advisor.The proceeds from this round of financing will be used to advance the clinical development and commercialization of multiple existing core pipelines.

Innovation in medical devices often stems from breakthroughs and advancements in biomedical materials. As a novel class of biomedical materials, medical microspheres hold broad application prospects in areas such as controlled drug release, drug delivery, tissue filling, and regeneration.Sustained-release microspheres represent a key direction for innovative R&D in high-end sustained- and controlled-release formulations both domestically and internationally. Compared with conventional formulations, sustained-release microsphere formulations can not only prolong drug action, effectively reduce adverse reactions, and maintain stable plasma drug concentrations, but also decrease dosing frequency, thereby improving patient compliance. In the field of interventional oncology, drug-eluting embolic microspheres have been widely applied in the interventional treatment market for liver cancer and are being actively expanded to other solid tumors such as lung cancer and breast cancer. Furthermore, the FDA has recently approved embolization therapies for conditions including arthritis and benign prostatic hyperplasia.

Anti-aging has always been an enduring pursuit in the field of medical aesthetics, particularly in facial rejuvenation, which commands a substantial consumer market. Injectable microspheres used in aesthetic medicine, once delivered into the deep layers of the skin, continuously stimulate human fibroblasts to secrete and synthesize collagen. The newly formed collagen gradually restores volume to previously deficient areas and repairs the skin’s elastic fiber network, thereby diminishing facial wrinkles and depressions from the inside out and from superficial to deep layers. This process helps restore a youthful appearance to the skin, achieving effective anti-aging results.Products derived from underlying technologies, such as sustained-release microspheres, drug-loaded embolic microspheres, and medical aesthetic microspheres, hold immense market potential.

Suzhou Haowei Micro Medical Technology Co., Ltd. is a technology-driven enterprise centered on “drug delivery” technology, dedicated to providing novel products and therapeutic solutions for clinical practice through continuous research and development and innovation.The company has established a professional microspheres technology team with multidisciplinary expertise spanning polymer science, pharmaceutics, biology, and medicine. The team possesses extensive experience in the full-cycle product development process, including microsphere design, monomer screening and modification, formulation of shaping and polymerization systems, and evaluation of drug sustained-release profiles. The company offers development services for sustained-release microsphere formulations (covering various drugs such as triamcinolone acetonide, risperidone, leuprorelin, and octreotide) as well as medical aesthetic materials based on PLLA/PLLA-PEG microspheres. Several of the company’s products are first-of-their-kind in China. Its key R&D pipeline of innovative products, including drug-loaded microspheres, biodegradable microspheres, radioactive microspheres, embolic balloon microcatheters, and steerable microcatheters, is progressively entering clinical trials and regulatory submission stages.

BITOLA CAPITAL is the pioneer of flexible investment banking in the global life sciences sector. As a financial services firm dedicated to the global life and health sciences industry, we hold leading positions in investment banking, financial services for entrepreneurs and small businesses, asset management, commercialization services, and government industrial park incubation.

Our mission is to ensure the enduring vitality of life. We are committed to serving as the beacon at the dawn of the digital age, illuminating the path toward excellence for life sciences enterprises amidst continuous transformation. By matching them with the most suitable value-oriented investment institutions globally, we strive to become a premier platform where resources and capital mutually identify one another and resonate in value.

Our vision is to become an innovative beacon for investment banking in the global life sciences sector. We believe that the intrinsic link between life sciences and value investing is the origin point for leading the great enterprises of the next century. We are committed to working with technological innovators and value investors in China and around the world to co-create new models that will shape the future. Upholding a global perspective and pursuing daily renewal, we walk alongside all like-minded partners to continuously gain insights into, explore, and connect through this shared consensus.